
Sign up to save your podcasts
Or


Listen in as our expert panel tackles real-world questions about GLP-1 agonists, from starting them and setting expectations with patients to strategies for switching agents. You’ll also hear them review key considerations to limit muscle loss with GLP-1 agonist use and discuss why some patients hit a plateau or don’t respond to GLP-1 agonists.
Special guests:
Panelists on TRC’s Editorial Advisory Board:
For the purposes of disclosure Dr. Jennifer Clements reports relevant financial relationships with Novo Nordisk (Ozempic, Rybelsus), Eli Lilly (Zepbound, tirzepatide) [speakers bureau].
The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
This podcast is an excerpt from one of TRC’s monthly live CE webinars, the full webinar originally aired in February 2026.
🏷️ Use code mt1026 at checkout for 10% off.
TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist’s Letter, Pharmacy Technician’s Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
Claim Credit
Clinical Resources:
Send us Fan Mail
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.
By TRC Healthcare | Pharmacist's Letter | Prescriber Insights | Pharmacy Technician's Letter4.8
3636 ratings
Listen in as our expert panel tackles real-world questions about GLP-1 agonists, from starting them and setting expectations with patients to strategies for switching agents. You’ll also hear them review key considerations to limit muscle loss with GLP-1 agonist use and discuss why some patients hit a plateau or don’t respond to GLP-1 agonists.
Special guests:
Panelists on TRC’s Editorial Advisory Board:
For the purposes of disclosure Dr. Jennifer Clements reports relevant financial relationships with Novo Nordisk (Ozempic, Rybelsus), Eli Lilly (Zepbound, tirzepatide) [speakers bureau].
The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
This podcast is an excerpt from one of TRC’s monthly live CE webinars, the full webinar originally aired in February 2026.
🏷️ Use code mt1026 at checkout for 10% off.
TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist’s Letter, Pharmacy Technician’s Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
Claim Credit
Clinical Resources:
Send us Fan Mail
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.

701 Listeners

504 Listeners

101 Listeners

298 Listeners

264 Listeners

3,374 Listeners

1,150 Listeners

732 Listeners

194 Listeners

518 Listeners

437 Listeners

375 Listeners

152 Listeners

3 Listeners

6 Listeners